Point72 Asset Management L.P. Decreases Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Point72 Asset Management L.P. decreased its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 79.0% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 317,114 shares of the company's stock after selling 1,189,532 shares during the period. Point72 Asset Management L.P. owned approximately 1.35% of UroGen Pharma worth $3,377,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of URGN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of UroGen Pharma by 4.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company's stock valued at $231,000 after acquiring an additional 969 shares during the last quarter. Rhumbline Advisers grew its stake in shares of UroGen Pharma by 2.8% during the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company's stock worth $546,000 after purchasing an additional 1,402 shares during the period. MetLife Investment Management LLC increased its holdings in shares of UroGen Pharma by 13.6% during the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company's stock valued at $242,000 after purchasing an additional 2,727 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of UroGen Pharma by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company's stock valued at $996,000 after purchasing an additional 3,024 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in shares of UroGen Pharma by 24.6% in the 4th quarter. Legal & General Group Plc now owns 19,845 shares of the company's stock valued at $211,000 after purchasing an additional 3,920 shares during the period. Institutional investors and hedge funds own 91.29% of the company's stock.

UroGen Pharma Stock Up 2.7%

Shares of URGN traded up $0.11 during mid-day trading on Monday, reaching $4.19. The company's stock had a trading volume of 2,328,338 shares, compared to its average volume of 672,612. The company's 50 day moving average is $10.03 and its 200 day moving average is $10.65. The stock has a market cap of $193.19 million, a PE ratio of -1.33 and a beta of 0.66. UroGen Pharma Ltd. has a 12-month low of $3.42 and a 12-month high of $20.70. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million. Equities analysts anticipate that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on URGN shares. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price target on the stock. D. Boral Capital reissued a "buy" rating and set a $25.00 target price on shares of UroGen Pharma in a research note on Thursday, May 8th. The Goldman Sachs Group dropped their target price on shares of UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating for the company in a report on Thursday. HC Wainwright cut shares of UroGen Pharma from a "buy" rating to a "neutral" rating in a research note on Thursday. Finally, Guggenheim cut their target price on UroGen Pharma from $40.00 to $15.00 and set a "buy" rating for the company in a research note on Friday. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $27.43.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.